![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PRELP |
Gene summary for PRELP |
![]() |
Gene information | Species | Human | Gene symbol | PRELP | Gene ID | 5549 |
Gene name | proline and arginine rich end leucine rich repeat protein | |
Gene Alias | MST161 | |
Cytomap | 1q32.1 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | P51888 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5549 | PRELP | cirrhotic3 | Human | Liver | Cirrhotic | 3.16e-05 | 3.11e-01 | 0.0215 |
5549 | PRELP | HCC1 | Human | Liver | HCC | 1.45e-07 | 1.03e+00 | 0.5336 |
5549 | PRELP | HCC2 | Human | Liver | HCC | 7.22e-18 | 1.51e+00 | 0.5341 |
5549 | PRELP | HCC5 | Human | Liver | HCC | 5.86e-17 | 1.40e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000756812 | Liver | Cirrhotic | aging | 117/4634 | 339/18723 | 3.13e-05 | 3.91e-04 | 117 |
GO:000756822 | Liver | HCC | aging | 185/7958 | 339/18723 | 4.28e-06 | 5.50e-05 | 185 |
GO:00075691 | Liver | HCC | cell aging | 73/7958 | 132/18723 | 2.00e-03 | 1.01e-02 | 73 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRELP | SNV | Missense_Mutation | rs767859381 | c.1013N>T | p.Ala338Val | p.A338V | P51888 | protein_coding | tolerated(0.25) | benign(0.027) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRELP | SNV | Missense_Mutation | c.77C>A | p.Pro26Gln | p.P26Q | P51888 | protein_coding | deleterious_low_confidence(0.03) | benign(0.003) | TCGA-D8-A1XF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
PRELP | SNV | Missense_Mutation | c.163C>T | p.Pro55Ser | p.P55S | P51888 | protein_coding | deleterious(0.02) | probably_damaging(0.941) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PRELP | SNV | Missense_Mutation | rs775055111 | c.727N>A | p.Ala243Thr | p.A243T | P51888 | protein_coding | tolerated(0.44) | benign(0.051) | TCGA-E9-A5FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRELP | insertion | Frame_Shift_Ins | novel | c.705_706insGTGGTCAACAAACCTTCACTGATTGAGC | p.Met236ValfsTer26 | p.M236Vfs*26 | P51888 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
PRELP | SNV | Missense_Mutation | novel | c.705G>T | p.Lys235Asn | p.K235N | P51888 | protein_coding | tolerated(0.11) | benign(0.009) | TCGA-C5-A1M7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PRELP | SNV | Missense_Mutation | c.433N>A | p.Val145Met | p.V145M | P51888 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
PRELP | SNV | Missense_Mutation | c.941N>G | p.Glu314Gly | p.E314G | P51888 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AA-3693-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
PRELP | SNV | Missense_Mutation | novel | c.821N>G | p.Asn274Ser | p.N274S | P51888 | protein_coding | tolerated(0.41) | possibly_damaging(0.646) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
PRELP | SNV | Missense_Mutation | rs571164341 | c.307N>T | p.Arg103Cys | p.R103C | P51888 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |